SCHEMBL27098770

SCHEMBL27098770

Cn1c2ccncc2c2ccc(-c3cnc(CN4CCC(CCN5CCN(c6ccc7c(c6)C(=O)N(C6CCC(=O)NC6=O)C7=O)CC5)CC4)c(F)c3)cc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 2/20 0.45
▸ BRD9 Q9H8M2 2/20 0.45
▸ CRBN Q96SW2 8/20 0.42
▸ ITK Q08881 3/20 0.42
▸ IL2 P60568 1/20 0.42
▸ MELK Q14680 1/20 0.42
▸ ALK Q9UM73 1/20 0.42
▸ PLK4 O00444 2/20 0.41
▸ CCNC P24863 1/20 0.41
▸ CDK8 P49336 1/20 0.41
▸ IRAK1 P51617 1/20 0.41
▸ NTRK3 Q16288 1/20 0.41
▸ HASPIN Q8TF76 1/20 0.41
▸ CDK19 Q9BWU1 1/20 0.41
▸ IRAK4 Q9NWZ3 1/20 0.41
▸ IRAK3 Q9Y616 1/20 0.41
▸ ESR1 P03372 1/20 0.41
▸ EGFR P00533 3/20 0.41
▸ AR P10275 1/20 0.40
▸ BTK Q06187 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29857405 1.00 RAF1 (0.45) RAF1BRD9CRBNITKIL2
SCHEMBL29857526 0.93 RAF1 (0.43) RAF1BRD9CRBNITKIL2
SCHEMBL27099472 0.93 RAF1 (0.43) RAF1BRD9CRBNITKIL2
SCHEMBL27099324 0.90 RAF1 (0.45) RAF1BRD9CRBNITKIL2
SCHEMBL27099271 0.89 BRD9 (0.49) RAF1BRD9CRBNITKIL2
SCHEMBL27098776 0.89 CRBN (0.47) RAF1BRD9CRBNITKIL2
SCHEMBL29857065 0.89 CRBN (0.47) RAF1BRD9CRBNITKIL2
SCHEMBL27099253 0.88 BRD9 (0.47) RAF1BRD9CRBNITKIL2
SCHEMBL27099338 0.88 CRBN (0.45) RAF1BRD9CRBNITKIL2
SCHEMBL29857130 0.87 BTK (0.46) RAF1BRD9CRBNITKIL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217962-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-07-04 — — US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 — — US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 — — US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN RAF1 974/4885BRD9 1284/4885CRBN 3/4885
US-20240217962-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE VHL, CRBN, MAPT RAF1 1272/4885BRD9 2148/4885CRBN 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback